
Ilaria Faggiani
Articles
-
Aug 21, 2024 |
mdpi.com | Ilaria Faggiani |Ferdinando D’Amico |Federica Furfaro |Alessandra Zilli
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Aug 13, 2024 |
mdpi.com | Ilaria Faggiani |Jacopo Fanizza |Ferdinando D’Amico |Mariangela Allocca
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Mar 7, 2024 |
mdpi.com | Francesca Bernardi |Ferdinando D’Amico |Sarah Bencardino |Ilaria Faggiani
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
-
Jul 30, 2023 |
mdpi.com | Ferdinando D’Amico |Francesca Bernardi |Sarah Bencardino |Ilaria Faggiani
Abstract:Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that negatively impacts patients’ quality of life. In the last decades, the therapeutic options available for the management of patients with moderate to severe UC have increased significantly, including not only biological drugs but also small molecules. However, there is a persistent need to develop new drugs that act on new targets while minimizing the risk of adverse events.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →